Cargando…
CNS Demyelination with TNF-α Blockers
Tumor necrosis factor–α (TNF-α) blockers are a popular therapeutic choice in a number of inflammatory diseases. Thus far, five TNF- α blockers have been approved for clinical use (etanercept, infliximab, adalimumab, golimumab. and certolizumab). Despite being considered relatively safe, serious side...
Autores principales: | Kemanetzoglou, Elissavet, Andreadou, Elisabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364240/ https://www.ncbi.nlm.nih.gov/pubmed/28337644 http://dx.doi.org/10.1007/s11910-017-0742-1 |
Ejemplares similares
-
Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices
por: Chou, I-Jun, et al.
Publicado: (2016) -
Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016) -
Plasma Exchange for Treatment of Refractory Demyelination
por: Cronin, Michael, et al.
Publicado: (2020) -
Multiple Sclerosis Management During the COVID-19 Pandemic
por: Hollen, Chris, et al.
Publicado: (2022) -
The Management of Lower Urinary Tract Dysfunction in Multiple Sclerosis
por: Tornic, Jure, et al.
Publicado: (2018)